We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Viral Panel Enables Simultaneous Testing for SARS-CoV-2 and Common Respiratory Viruses

By LabMedica International staff writers
Posted on 02 Nov 2021
Print article
Image: Dr. Ravindra Kolhe (Photo courtesy of Augusta University)
Image: Dr. Ravindra Kolhe (Photo courtesy of Augusta University)

Researchers have developed a viral panel that enables the simultaneous testing for SARS-CoV-2 along with numerous common respiratory viruses, that tells us whether other viruses also are at play in patients hard hit by COVID.

This new genetic epidemiology tool developed by researchers at Augusta University (Augusta, GA, USA) along with Illumina (San Diego, CA, USA) provides detailed genetic information about the viruses present when packaged with a molecular immunology model called Nextstrain. It also enables researchers to assess the novel viral variants that are circulating in a state or nation and patterns for their spread with the goal of helping predict and mitigate future outbreaks.

The researchers developed a 41-virus panel that includes four common human coronaviruses that have been causing colds in people for years as well as SARS-CoV-2, and other players like RSV, respiratory syncytial virus, which also causes a typically mild cold, and more than a dozen influenza viruses. Standard SARS-CoV-2 testing uses polymerase chain reaction, or PCR, which can tell you if the virus is present, but the technique they are using for the panel actually sequences the viral genome enabling detection of variants. It also details changes in the larger, conserved region of the virus that occur essentially every time it multiplies, which indicates it has found a host organism, like a human. While those small changes in the conserved region of the virus don’t impact clinical outcome, they do provide a sort of genomic stamp of where the virus came from.

The unique molecular signature also is a way to know which cases are not connected. The interactive visualization model they use to watch viral spread play out can also track the movement of variants, like Delta, that do have direct clinical consequences like degree of contagiousness and resulting sickness. Some of the human movement may happen before the individual realizes he is positive. Knowing precisely which viruses are present is important because, while there is some commonality among the respiratory viruses, the treatments tend to be different, but there is not much crossover data on how much to date. The new study shows that genomic epidemiology is essential in predicting disease transmission and patterns of transmission, including the potential to recognize a likely resurgence.

“We are concerned that because most of us are no longer wearing masks or social distancing and have mostly resumed our normal schedules that one consequence will be more coinfections,” said Dr. Ravindra Kolhe, director of the Georgia Esoteric and Molecular Laboratory, or GEM Lab, at the Medical College of Georgia at Augusta University. “We feel this is a good tool to have ready when the flu and cold season hit.”

Related Links:
Augusta University 
Illumina 

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.